REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for blood cancer patients: canakinumab trial targets Low-Risk MDS and CMML
Disease control Recruiting nowThis study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The drug is a lab-made antibody that may help slow cancer growth and improve blood cell counts. About 76 adults will rece…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug combo offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a chemotherapy drug called CPX-351 in people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) that came back or didn't respond to standard treatment. The goal is to find the best dose that is safe and to se…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo attack on tough blood cancers: chemo plus transplant shows promise
Disease control Recruiting nowThis study tests a new approach for adults with aggressive blood cancers (like AML) that are likely to return after standard treatment. Participants receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and low-dose radiation, followed immediately by a stem cell …
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study is for people with certain blood cancers (like acute myeloid leukemia) that have a specific genetic change called a FLT3 mutation. The cancers have either come back or not responded to prior treatment. The trial tests a combination of three drugs—azacitidine, venetocla…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo attack on stubborn leukemia: chemo then transplant
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem …
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for tough blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called STX-0712 in people with advanced types of blood cancer (CMML or AML) who have run out of standard treatments. The main goal is to find a safe dose and see how the body handles the drug. About 105 participants will take part in this early-phase t…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Solu Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill Q702 aims to outsmart blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC